Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
82
RX.V Quote, Financials, Valuation and Earnings
Last price:
$12.8000
Seasonality move
:
6.66%
Day range:
$12.7200 - $12.8000
52-week range:
$9.2000 - $12.8000
Dividend yield:
1.56%
P/E ratio:
16.99x
P/S ratio:
3.47x
P/B ratio:
3.61x
Volume:
503
Avg. volume:
4.7K
1-year change:
10.82%
Market cap:
$144.2M
Revenue:
$35M
EPS (TTM):
$0.75
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RX.V
BioSyent, Inc.
|
$10.1M | -- | 17.09% | -- | $13.5000 |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RX.V
BioSyent, Inc.
|
$12.8000 | $13.5000 | $144.2M | 16.99x | $0.05 | 1.56% | 3.47x |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
HEAL.CX
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
$0.05 | -- | $9.7M | -- | $0.00 | 0% | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
$0.0200 | -- | $205.5K | 0.52x | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RX.V
BioSyent, Inc.
|
2.19% | 0.860 | 0.69% | 4.07x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
HEAL.CX
|
-- | 0.000 | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
40.99% | -3.518 | 19.05% | 2.85x |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-3.43% | 1.456 | 20.53% | 0.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RX.V
BioSyent, Inc.
|
$9.1M | $3.4M | 22.62% | 23.23% | 27.89% | $2.5M |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -$1.1M | -1117.27% | -- | -- | -$408.2K |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -$72.1K | -- | -- | -- | -$92.1K |
BioSyent, Inc. vs. Competitors
-
Which has Higher Returns RX.V or COOL.CX?
Core One Labs, Inc. has a net margin of 21.95% compared to BioSyent, Inc.'s net margin of --. BioSyent, Inc.'s return on equity of 23.23% beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RX.VBioSyent, Inc.74.17% $0.23 $40.8M COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About RX.V or COOL.CX?
BioSyent, Inc. has a consensus price target of $13.5000, signalling upside risk potential of 5.47%. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that BioSyent, Inc. has higher upside potential than Core One Labs, Inc., analysts believe BioSyent, Inc. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RX.VBioSyent, Inc.1 0 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is RX.V or COOL.CX More Risky?
BioSyent, Inc. has a beta of 0.436, which suggesting that the stock is 56.422% less volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock RX.V or COOL.CX?
BioSyent, Inc. has a quarterly dividend of $0.05 per share corresponding to a yield of 1.56%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioSyent, Inc. pays 29.49% of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend. BioSyent, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RX.V or COOL.CX?
BioSyent, Inc. quarterly revenues are $12.2M, which are larger than Core One Labs, Inc. quarterly revenues of --. BioSyent, Inc.'s net income of $2.7M is higher than Core One Labs, Inc.'s net income of --. Notably, BioSyent, Inc.'s price-to-earnings ratio is 16.99x while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioSyent, Inc. is 3.47x versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RX.VBioSyent, Inc.3.47x 16.99x $12.2M $2.7M COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns RX.V or CURE.X.CX?
Biocure Technology has a net margin of 21.95% compared to BioSyent, Inc.'s net margin of --. BioSyent, Inc.'s return on equity of 23.23% beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RX.VBioSyent, Inc.74.17% $0.23 $40.8M CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About RX.V or CURE.X.CX?
BioSyent, Inc. has a consensus price target of $13.5000, signalling upside risk potential of 5.47%. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that BioSyent, Inc. has higher upside potential than Biocure Technology, analysts believe BioSyent, Inc. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings RX.VBioSyent, Inc.1 0 0 CURE.X.CXBiocure Technology0 0 0 -
Is RX.V or CURE.X.CX More Risky?
BioSyent, Inc. has a beta of 0.436, which suggesting that the stock is 56.422% less volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RX.V or CURE.X.CX?
BioSyent, Inc. has a quarterly dividend of $0.05 per share corresponding to a yield of 1.56%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioSyent, Inc. pays 29.49% of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend. BioSyent, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RX.V or CURE.X.CX?
BioSyent, Inc. quarterly revenues are $12.2M, which are larger than Biocure Technology quarterly revenues of --. BioSyent, Inc.'s net income of $2.7M is higher than Biocure Technology's net income of --. Notably, BioSyent, Inc.'s price-to-earnings ratio is 16.99x while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioSyent, Inc. is 3.47x versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RX.VBioSyent, Inc.3.47x 16.99x $12.2M $2.7M CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns RX.V or HEAL.CX?
has a net margin of 21.95% compared to BioSyent, Inc.'s net margin of --. BioSyent, Inc.'s return on equity of 23.23% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RX.VBioSyent, Inc.74.17% $0.23 $40.8M HEAL.CX-- -- -- -
What do Analysts Say About RX.V or HEAL.CX?
BioSyent, Inc. has a consensus price target of $13.5000, signalling upside risk potential of 5.47%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that BioSyent, Inc. has higher upside potential than , analysts believe BioSyent, Inc. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings RX.VBioSyent, Inc.1 0 0 HEAL.CX0 0 0 -
Is RX.V or HEAL.CX More Risky?
BioSyent, Inc. has a beta of 0.436, which suggesting that the stock is 56.422% less volatile than S&P 500. In comparison has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RX.V or HEAL.CX?
BioSyent, Inc. has a quarterly dividend of $0.05 per share corresponding to a yield of 1.56%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioSyent, Inc. pays 29.49% of its earnings as a dividend. pays out -- of its earnings as a dividend. BioSyent, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RX.V or HEAL.CX?
BioSyent, Inc. quarterly revenues are $12.2M, which are larger than quarterly revenues of --. BioSyent, Inc.'s net income of $2.7M is higher than 's net income of --. Notably, BioSyent, Inc.'s price-to-earnings ratio is 16.99x while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioSyent, Inc. is 3.47x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RX.VBioSyent, Inc.3.47x 16.99x $12.2M $2.7M HEAL.CX-- -- -- --
-
Which has Higher Returns RX.V or LOBE.CX?
Lobe Sciences Ltd. has a net margin of 21.95% compared to BioSyent, Inc.'s net margin of --. BioSyent, Inc.'s return on equity of 23.23% beat Lobe Sciences Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RX.VBioSyent, Inc.74.17% $0.23 $40.8M LOBE.CXLobe Sciences Ltd.-- -$0.01 $5.9M -
What do Analysts Say About RX.V or LOBE.CX?
BioSyent, Inc. has a consensus price target of $13.5000, signalling upside risk potential of 5.47%. On the other hand Lobe Sciences Ltd. has an analysts' consensus of -- which suggests that it could grow by 14192.33%. Given that Lobe Sciences Ltd. has higher upside potential than BioSyent, Inc., analysts believe Lobe Sciences Ltd. is more attractive than BioSyent, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RX.VBioSyent, Inc.1 0 0 LOBE.CXLobe Sciences Ltd.0 0 0 -
Is RX.V or LOBE.CX More Risky?
BioSyent, Inc. has a beta of 0.436, which suggesting that the stock is 56.422% less volatile than S&P 500. In comparison Lobe Sciences Ltd. has a beta of 0.215, suggesting its less volatile than the S&P 500 by 78.507%.
-
Which is a Better Dividend Stock RX.V or LOBE.CX?
BioSyent, Inc. has a quarterly dividend of $0.05 per share corresponding to a yield of 1.56%. Lobe Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioSyent, Inc. pays 29.49% of its earnings as a dividend. Lobe Sciences Ltd. pays out -- of its earnings as a dividend. BioSyent, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RX.V or LOBE.CX?
BioSyent, Inc. quarterly revenues are $12.2M, which are larger than Lobe Sciences Ltd. quarterly revenues of --. BioSyent, Inc.'s net income of $2.7M is higher than Lobe Sciences Ltd.'s net income of -$1.1M. Notably, BioSyent, Inc.'s price-to-earnings ratio is 16.99x while Lobe Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioSyent, Inc. is 3.47x versus -- for Lobe Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RX.VBioSyent, Inc.3.47x 16.99x $12.2M $2.7M LOBE.CXLobe Sciences Ltd.-- -- -- -$1.1M
-
Which has Higher Returns RX.V or NSHS.CX?
NanoSphere Health Sciences, Inc. has a net margin of 21.95% compared to BioSyent, Inc.'s net margin of --. BioSyent, Inc.'s return on equity of 23.23% beat NanoSphere Health Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RX.VBioSyent, Inc.74.17% $0.23 $40.8M NSHS.CXNanoSphere Health Sciences, Inc.-- -$0.00 -$1.8M -
What do Analysts Say About RX.V or NSHS.CX?
BioSyent, Inc. has a consensus price target of $13.5000, signalling upside risk potential of 5.47%. On the other hand NanoSphere Health Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that BioSyent, Inc. has higher upside potential than NanoSphere Health Sciences, Inc., analysts believe BioSyent, Inc. is more attractive than NanoSphere Health Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RX.VBioSyent, Inc.1 0 0 NSHS.CXNanoSphere Health Sciences, Inc.0 0 0 -
Is RX.V or NSHS.CX More Risky?
BioSyent, Inc. has a beta of 0.436, which suggesting that the stock is 56.422% less volatile than S&P 500. In comparison NanoSphere Health Sciences, Inc. has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.292%.
-
Which is a Better Dividend Stock RX.V or NSHS.CX?
BioSyent, Inc. has a quarterly dividend of $0.05 per share corresponding to a yield of 1.56%. NanoSphere Health Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioSyent, Inc. pays 29.49% of its earnings as a dividend. NanoSphere Health Sciences, Inc. pays out -- of its earnings as a dividend. BioSyent, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RX.V or NSHS.CX?
BioSyent, Inc. quarterly revenues are $12.2M, which are larger than NanoSphere Health Sciences, Inc. quarterly revenues of --. BioSyent, Inc.'s net income of $2.7M is higher than NanoSphere Health Sciences, Inc.'s net income of -$13.1K. Notably, BioSyent, Inc.'s price-to-earnings ratio is 16.99x while NanoSphere Health Sciences, Inc.'s PE ratio is 0.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioSyent, Inc. is 3.47x versus -- for NanoSphere Health Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RX.VBioSyent, Inc.3.47x 16.99x $12.2M $2.7M NSHS.CXNanoSphere Health Sciences, Inc.-- 0.52x -- -$13.1K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
